Methylphenidate

( DrugBank: Methylphenidate / KEGG DRUG: Methylphenidate )

7 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	8
13	Multiple sclerosis/Neuromyelitis optica	5
34	Neurofibromatosis	1
84	Sarcoidosis	3

ID	Disease name (Link within this page)	Number of trials
113	Muscular dystrophy	1
179	Williams syndrome	1
206	Fragile X syndrome	2

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

trials per page:

Showing 1 to 8 of 8 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05669170 (ClinicalTrials.gov)	January 2024	16/12/2022	Methylphenidate for Apathy in Veterans With Parkinson's Disease	Evaluating Safety and Potential Benefit of Methylphenidateas a Symptomatic Treatment for Apathy in V ...	Parkinson Disease;Apathy	Behavioral: Psychosocial intervention;Drug: Methylphenidate	Ralph H. Johnson VA Medical Center	NULL	Not yet recruiting	40 Years	N/A	All	60	Phase 2	NULL
2	NCT02879136 (ClinicalTrials.gov)	December 2016	23/6/2016	TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkins ...	TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkins ...	Parkinson's Disease, Idiopathic	Drug: Methylphenidate;Other: Physical Therapy;Drug: Atomoxetine	Hubert Fernandez	NULL	Recruiting	18 Years	90 Years	All	42	Early Phase 1	United States
3	NCT01244269 (ClinicalTrials.gov)	December 2010	18/11/2010	The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.	Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidatefor Non-motor and Post ...	Parkinson's Disease	Drug: Methylphenidate;Drug: Placebo 10;Drug: Placebo 20	Laval University	Fonds de la Recherche en Santé du Québec;Quebec Memory and Motor Skills Disorders Research Center	Terminated	N/A	75 Years	Both	6	Phase 4	Canada
4	EUCTR2009-012643-42-NL (EUCTR)	06/01/2010	30/11/2009	Freezing of gait in Parkinson's disease: in search of the underlying mechanism and the application o ...	Freezing of gait in Parkinson's disease: in search of the underlying mechanism and the application o ...	Parkinson's disease, in particular the symptom Freezing of Gait	Trade Name: Ritalin Product Name: Not applicable Product Code: Not applicable INN or Proposed INN: METH ...	University Medical Center Groningen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands
5	NCT00914095 (ClinicalTrials.gov)	October 2009	2/6/2009	Study of Methylphenidateto Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGA ...	Study of Methylphenidateto Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Rand ...	Parkinson's Disease;Gait Disorders, Neurologic;Dementia	Drug: methylphenidate;Drug: placebo	University Hospital, Lille	NULL	Completed	30 Years	80 Years	Both	69	Phase 4	France
6	NCT00526630 (ClinicalTrials.gov)	December 2007	5/9/2007	Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease	Methylphenidatefor the Treatment of Gain Impairment in Parkinson's Disease: a Randomized Double-Blin ...	Parkinson's Disease;Gait Impairment	Drug: Methylphenidate (MPD);Drug: Placebo	University of Cincinnati	Michael J. Fox Foundation for Parkinson's Research	Completed	35 Years	85 Years	All	23	Phase 4	United States
7	NCT00393562 (ClinicalTrials.gov)	March 2006	26/10/2006	Comparison of Modafinil and Methylphenidatein Treatment of Excessive Daytime Sleepiness in Patients ...	Comparison of Modafinil and Methylphenidatein Treatment of Excessive Daytime Sleepiness in Patients ...	Parkinson's Disease	Drug: modafinil;Drug: methylphenidate	Department of Veterans Affairs	NULL	Withdrawn	50 Years	80 Years	Both	0	N/A	United States
8	NCT00359723 (ClinicalTrials.gov)	July 2004	31/7/2006	Methylphenidate and Parkinson's Disease	Subacute Trial of Methylphenidate in Parkinson's Disease	Parkinson's Disease	Drug: methylphenidate	Oregon Health and Science University	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	21 Years	N/A	All	13	Phase 2	United States

First Previous1Next Last

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

trials per page:

Showing 1 to 5 of 5 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03185065 (ClinicalTrials.gov)	October 4, 2017	9/6/2017	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Fatigue in Multiple Sclerosis	Drug: Amantadine;Drug: Modafinil;Drug: Methylphenidate;Drug: Placebos	Johns Hopkins University	Patient-Centered Outcomes Research Institute	Completed	18 Years	N/A	All	141	Phase 3	United States
2	NCT02286557 (ClinicalTrials.gov)	October 2014	16/10/2014	Testing the Effects of Methylphenidate on Multiple Sclerosis	Testing the Effects of Methylphenidateon Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Pl ...	Fatigue in Multiple Sclerosis	Drug: Methelphenidate;Drug: Placebo	Kessler Foundation	NULL	Not yet recruiting	18 Years	65 Years	Both	36	Phase 2	NULL
3	NCT01896700 (ClinicalTrials.gov)	July 2013	8/7/2013	Methylphenidate to Improve Balance and Walking in MS	Methylphenidate to Improve Balance and Walking in MS	Multiple Sclerosis	Drug: Methylphenidate;Drug: Placebo	Oregon Health and Science University	Portland VA Medical Center	Completed	20 Years	65 Years	All	24	Phase 2/Phase 3	United States
4	NCT01879202 (ClinicalTrials.gov)	December 2012	7/11/2012	Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis	MethylphenidateModified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Do ...	Multiple Sclerosis;Fatigue	Drug: Methylphenidate modified release;Drug: Maltodextrin	Medical University of Vienna	NULL	Recruiting	18 Years	N/A	Both	96	Phase 2	Austria
5	EUCTR2012-003418-15-AT (EUCTR)	23/10/2012	09/11/2012	Methylphenidate modified release as treatment of MS-associated fatigue.	Methylphenidatemodified release as treatment option of MS-associated fatigue. A single-center random ...	Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic ap ...	Trade Name: Ritalin LA 20mg capsules Product Name: Methylphenidatemodified release 20 mg INN or Propos ...	Medizinische Universität Wien	NULL	Not Recruiting			Female: yes Male: yes	96	Phase 2	Austria

First Previous1Next Last

34. Neurofibromatosis

Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00169611 (ClinicalTrials.gov)	January 2004	9/9/2005	NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate	Comportemental and Neuropsychologic Study of Children With Neurofibromatosis Type 1 Treated by Methy ...	Neurofibromatosis Type 1	Drug: methylphenidate	Hospices Civils de Lyon	NULL	Completed	7 Years	12 Years	Both	80	Phase 4	France

First Previous1Next Last

84. Sarcoidosis

Clinical trials : 149 / Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02643732 (ClinicalTrials.gov)	November 2016	23/12/2015	Fatigue in Sarcoidosis - Treatment With Methylphenidate	Fatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoi ...	Sarcoidosis;Fatigue	Drug: Methylphenidate (overencapsulated);Drug: Placebo (Over-encapsulated tablet)	University of East Anglia	Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)	Recruiting	18 Years	N/A	All	30	N/A	United Kingdom
2	EUCTR2016-000342-60-GB (EUCTR)	21/06/2016	06/02/2019	Fatigue and Sarcoidosis: Treatment with Methylphenidate	Fatigue in Sarcoidosis - A feasibility study investigating the treatment of fatigue in stable sarcoi ...	Sarcoidosis-associated fatigue (Patients with stable sarcoidosis and chronic fatigue) MedDRA version ...	Trade Name: Methylphenidate Product Name: Methylphenidate10mg tablets Product Code: NA INN or Proposed ...	Norfolk and Norwich University Hospital	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	United Kingdom
3	NCT00361387 (ClinicalTrials.gov)	June 2006	7/8/2006	Use of Focalin for Fatigue in Sarcoidosis	Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in t ...	Sarcoidosis	Drug: d-methylphenidate	University of Cincinnati	NULL	Completed	18 Years	N/A	Both	12	Phase 4	United States

First Previous1Next Last

113. Muscular dystrophy

Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01421992 (ClinicalTrials.gov)	June 2008	1/6/2011	Methylphenidate in Myotonic Dystrophy Type 1	Phase 2/3 Study of Efficacy and Tolerability of Methylphenidatein the Treatment of Excessive Daytime ...	Dystrophia Myotonica 1	Drug: Methylphenidate;Drug: Placebo	Laval University	NULL	Completed	18 Years	65 Years	Both	28	Phase 2/Phase 3	Canada

First Previous1Next Last

179. Williams syndrome

Clinical trials : 5 / Drugs : 14 - (DrugBank : 7) / Drug target genes : 8 - Drug target pathways : 32

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00768820 (ClinicalTrials.gov)	May 2001	7/10/2008	The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome	The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS) ...	Velocardiofacial Syndrome;Williams Syndrome;Fragile X Syndrome	Drug: methylphenidate, fluoxetin, risperidone	The Chaim Sheba Medical Center	NULL	Recruiting	N/A	N/A	All	400	Phase 4	Israel

First Previous1Next Last

206. Fragile X syndrome

Clinical trials : 108 / Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05301361 (ClinicalTrials.gov)	February 1, 2023	8/3/2022	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities	Sensitivity of the NIH Toolbox Cognition Battery to Stimulant Treatment in Intellectual Disabilities ...	Intellectual Disability;Fragile X Syndrome;Down Syndrome;Attention Deficit Hyperactivity Disorder	Drug: Methylphenidate Oral Solution	University of California, Davis	NULL	Recruiting	6 Years	17 Years	All	68	Phase 1	United States
2	NCT00768820 (ClinicalTrials.gov)	May 2001	7/10/2008	The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome	The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS) ...	Velocardiofacial Syndrome;Williams Syndrome;Fragile X Syndrome	Drug: methylphenidate, fluoxetin, risperidone	The Chaim Sheba Medical Center	NULL	Recruiting	N/A	N/A	All	400	Phase 4	Israel

First Previous1Next Last